Gastrointestinal Histoplasmosis: Unveiling the Colon Cancer Facade in Crohn's Disease

Author:

Ayoub Malek1,Alharfi Mohammad2,Polamraju Vinathi1,Alhobayb Tamara1,Byrnes Kathleen1,Gremida Anas1

Affiliation:

1. Washington University School of Medicine

2. Imam Mohammad Ibn Saud Islamic University

Abstract

Abstract Background: The therapeutic landscape for inflammatory bowel diseases (IBD) has expanded with the advent of tumor necrosis factor-α (TNF) inhibitors, yet hurdles persist despite these strides. One such challenge arises from the increased vulnerability to opportunistic infections, notably histoplasmosis. Although histoplasmosis typically resolves on its own in individuals with healthy immune systems, its unconventional gastrointestinal manifestations in IBD patients can pose a diagnostic conundrum. Case presentation: Here, we delve into the narrative of a 72-year-old woman diagnosed with Crohn's disease on infliximab monotherapy presented with escalating lower abdominal discomfort, nausea, vomiting, bloody diarrhea, and unintended weight loss over the preceding four weeks. Magnetic resonance enterography (MRE) highlighted a 5 cm thickened wall and restricted diffusion in the transverse colon, raising suspicions of malignancy. Colonoscopy revealed a sizable 15 mm deep and cratered transverse colon ulcer, prompting concern for colon cancer. However, a biopsy from the ulcer only revealed acute nonspecific inflammation. Given the patient's deteriorating condition and persistent neoplasm suspicion, she underwent total abdominal colectomy with ileorectal anastomosis. Surgical pathology confirmed multifocal transmural fungal colitis, consistent with histoplasmosis. Conclusion: Clinicians should have a high index of suspicion for fungal colitis in patients previously in remission on immunosuppressive therapy and caution against dismissing histoplasmosis solely based on negative biopsy results. Repeated biopsy may be warranted to ensure comprehensive evaluation and accurate diagnosis.

Publisher

Research Square Platform LLC

Reference12 articles.

1. Clinical use of anti-TNF therapy and increased risk of infections;Ali T;Drug Healthc Patient Saf,2013

2. Histoplasmosis in Inflammatory Bowel Disease with Tumor Necrosis Factor-Alpha Inhibitors: Safe to Continue Biologics?;Jansson-Knodell CL;Dig Dis Sci,2021

3. Disseminated histoplasmosis; a threat in advanced HIV disease population in sub-Saharan Africa?;Oladele RO;Journal of Advances in Medicine and Medical Research,2021

4. Administration USFaD. REMICADE (infliximab) Label 2013 [Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103772s5359lbl.pdf.

5. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry;Lichtenstein GR;Am J Gastroenterol,2012

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3